RCMI Coordinating Center (RCMI CC) Header Logo

LaMonica Stewart

TitleAssociate Dean, School of Graduate Studies and Research
Faculty RankAssociate Professor
InstitutionMeharry Medical College
DepartmentSOGSR
Address1005 Dr. D. B. Todd Jr. Blvd.
WBS, Room 2118
Nashville TN 37208
Phone6153276749
vCardDownload vCard
    Other Positions
    TitleMember
    InstitutionVanderbilt Ingram Cancer Center
    DepartmentSignal Transduction/Cell Proliferation


    Collapse Overview 
    Collapse overview
    Dr. LaMonica Stewart is an Associate Professor in the Department of Biochemistry and Cancer Biology at Meharry Medical College. Since joining the Meharry faculty in 2004, Dr. Stewart has primarily performed research and been involved in the training of medical and Ph.D. graduate students. Her current research projects examine the regulation of prostate cancer growth and progression by compounds that activate the peroxisome proliferator activated receptor gamma (PPARg). Her laboratory uses human prostate cancer cell lines and xenograft mouse models to define the mechanisms by which PPARg agonists inhibit tumor cell proliferation and invasion. Her research has revealed that one class of PPAR agonists, the thiazolindinediones, regulates activation of the androgen receptor and alters expression of several proteins that control cell cycle progression. The data from these studies has also shown that the thiazolidinediones activate both PPAR dependent and PPAR-independent signaling pathways within human prostate cancer cells. The information gained from these studies will be used to identify new treatment strategies for early and late stage prostate cancer. Dr. Stewart is expanding her research program to include studies that examine the effect of PPARg ligands and anti-diabetic agents on other diseases of the prostate and urogenital system as well as the factors that control PPARg expression within the prostate. She also has begun to explore the effects of metformin and other antidiabetic agents on prostate cancer growth and progression. Dr. Stewart also serves as the Director of Graduate Studies for the Department of Biochemistry and Cancer Biology at Meharry. In this role, she advises students within the Biochemistry and Cancer Biology Ph.D. program and serves on multiple committees within the School of Graduate Studies and Research.

    Dr. Stewart is a 1991 magna cum laude graduate of Texas A&M University in College Station, TX, where she earned a B.S. in Biochemistry. She earned a Ph.D. in Pharmacology and Toxicology from the University of Texas Medical Branch in 1996. Following her doctoral training, Dr. Stewart completed postdoctoral fellowships at the National Cancer Institute in Bethesda, MD and Baylor College of Medicine.


    Collapse Research 
    Collapse research activities and funding
    F31GM014807     (STEWART, LAMONICA VANETTE)Mar 23, 1992
    NIH
    MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMS
    Role: Principal Investigator

    F32CA083277     (STEWART, LAMONICA VANETTE)Mar 1, 2001
    NIH
    VITAMIN D AND INHIBITION OF PROSTATE CANCER CELL GROWTH
    Role: Principal Investigator

    K01CA114253     (STEWART, LAMONICA VANETTE)Jul 1, 2006 - Jun 30, 2012
    NIH
    Regulation of Prostate Cancer Growth by PPARg Ligands
    Role: Principal Investigator

    R25CA214220     (STEWART, LAMONICA VANETTE)Sep 20, 2017 - Jul 31, 2023
    NIH
    Meharry summer undergraduate research experiences in cancer program
    Role: Principal Investigator

    R25CA281834     (STEWART, LAMONICA VANETTE)Sep 1, 2023 - Aug 31, 2028
    NIH
    The Meharry Cancer Summer Research Program (SuRP)
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Brown LK, Kanagasabai T, Li G, Celada SI, Rumph JT, Adunyah SE, Stewart LV, Chen Z. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis. Prostate. 2024 Jun; 84(9):877-887. PMID: 38605532.
      Citations:    Fields:    Translation:HumansCells
    2. Smith T, White T, Chen Z, Stewart LV. The KDM5 inhibitor PBIT reduces proliferation of castration-resistant prostate cancer cells via cell cycle arrest and the induction of senescence. Exp Cell Res. 2024 Apr 01; 437(1):113991. PMID: 38462208.
      Citations:    Fields:    Translation:HumansCells
    3. Koethe JR, Eeds A, Stewart LV, Haas DW, Hildreth JEK, Mallal S, Wanjalla C, Perkins J, Ahonkhai A, Dong X, Berhanu R, Dash C. The Tennessee Center for AIDS Research HIV Research Training Program for Minority High School and Undergraduate Students: Development, Implementation, and Early Outcomes. J Acquir Immune Defic Syndr. 2023 10 01; 94(2S):S42-S46. PMID: 37707847.
      Citations: 1     Fields:    Translation:Humans
    4. Williams SD, Smith TM, Stewart LV, Sakwe AM. Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists. Cells. 2022 09 27; 11(19). PMID: 36230969.
      Citations: 3     Fields:    Translation:HumansCells
    5. Olokpa E, Moss PE, Stewart LV. Crosstalk between the Androgen Receptor and PPAR Gamma Signaling Pathways in the Prostate. PPAR Res. 2017; 2017:9456020. PMID: 29181019.
      Citations:    
    6. Olokpa E, Bolden A, Stewart LV. The Androgen Receptor Regulates PPAR? Expression and Activity in Human Prostate Cancer Cells. J Cell Physiol. 2016 12; 231(12):2664-72. PMID: 26945682.
      Citations: 21     Fields:    Translation:HumansCells
    7. Bolden A, Bernard L, Jones D, Akinyeke T, Stewart LV. The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPAR?-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells. PPAR Res. 2012; 2012:929052. PMID: 22448169.
      Citations:    
    8. Akinyeke TO, Stewart LV. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPAR?-independent mechanism. Cancer Biol Ther. 2011 Jun 15; 11(12):1046-58. PMID: 21525782.
      Citations: 28     Fields:    Translation:HumansCells
    9. Moss PE, Lyles BE, Stewart LV. The PPAR? ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells. Exp Cell Res. 2010 Dec 10; 316(20):3478-88. PMID: 20932825.
      Citations: 23     Fields:    Translation:HumansCells
    10. Lyles BE, Akinyeke TO, Moss PE, Stewart LV. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle. 2009 Jan 15; 8(2):268-77. PMID: 19164938.
      Citations: 29     Fields:    Translation:HumansCells
    11. Stewart LV, Lyles B, Lin MF, Weigel NL. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol. 2005 Oct; 97(1-2):37-46. PMID: 16076555.
      Citations: 7     Fields:    Translation:HumansCells
    12. Stewart LV, Weigel NL. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate. 2005 Jun 15; 64(1):9-19. PMID: 15651061.
      Citations: 15     Fields:    Translation:HumansCells
    13. Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, Weigel NL, Mehta RG, Holick MF, Ray R. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 01; 10(23):8018-27. PMID: 15585637.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    14. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med (Maywood). 2004 Apr; 229(4):277-84. PMID: 15044710.
      Citations: 26     Fields:    Translation:HumansAnimals
    15. Stewart LV, Song K, Hsing AY, Danielpour D. Regulation of trespin expression by modulators of cell growth, differentiation, and apoptosis in prostatic epithelial cells. Exp Cell Res. 2003 Apr 01; 284(2):303-15. PMID: 12651162.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    16. Polek TC, Stewart LV, Ryu EJ, Cohen MB, Allegretto EA, Weigel NL. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology. 2003 Jan; 144(1):50-60. PMID: 12488329.
      Citations: 18     Fields:    Translation:HumansCells
    17. Chipuk JE, Stewart LV, Ranieri A, Song K, Danielpour D. Identification and characterization of a novel rat ov-serpin family member, trespin. J Biol Chem. 2002 Jul 19; 277(29):26412-21. PMID: 11986314.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    18. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000 Feb 15; 60(4):779-82. PMID: 10706079.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    19. Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, B?ttinger EP, Danielpour D, Wakefield LM. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res. 1999 Oct 01; 59(19):4834-42. PMID: 10519393.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    20. Lucia MS, Sporn MB, Roberts AB, Stewart LV, Danielpour D. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. J Cell Physiol. 1998 May; 175(2):184-92. PMID: 9525477.
      Citations: 12     Fields:    Translation:AnimalsCells
    21. Stewart LV, Thomas ML. Retinoids differentially regulate the proliferation of colon cancer cell lines. Exp Cell Res. 1997 Jun 15; 233(2):321-9. PMID: 9194494.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    Stewart's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (133)
    Explore
    _
    Co-Authors (5)
    Explore
    _
    Similar People (60)
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support